Applications of mannose-binding lectins and mannan glycoconjugates in nanomedicine
Source abstract
Abstract
Glycosylated nanoparticles (NPs) have drawn a lot of attention in the biomedical field over the past few decades, particularly in applications like targeted drug delivery. Mannosylated NPs and mannan-binding lectins/proteins (MBL/MBP) are emerging as promising tools for delivery of drugs, medicines, and enzymes to targeted tissues and cells as nanocarriers, enhancing their therapeutic benefits while avoiding the adverse effects of the drug. The occurrence of plenty of lectin receptors and their mannan ligands on cell surfaces makes them multifaceted carriers appropriate for specific delivery of bioactive drug materials to their targeted sites. Thus, the present review describes the tethering of mannose (Man) to several nanostructures, like micelles, liposomes, and other NPs, applicable for drug delivery systems. Bioadhesion through MBL-like receptors on cells has involvements applicable to additional arenas of science, for example gene delivery, tissue engineering, biomaterials, and nanotechnology. This review also focuses on the role of various aspects of drug/antigen delivery using (i) mannosylated NPs, (ii) mannosylated lectins, (iii) amphiphilic glycopolymer NPs, and (iv) natural mannan-containing polysaccharides, with most significant applications of MBL-based NPs as multivalent scaffolds, using different strategies. Graphical abstract Mannosylated NPs and/or MBL/MBP are coming up as viable and versatile tools as nanocarriers to deliver drugs and enzymes precisely to their target tissues or cells. The presence of abundant number of lectin receptors and their mannan ligands on cell surfaces makes them versatile carriers suitable for the targeted delivery of bioactive drugs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tsaneva M, Van Damme EJM (2020) 130 years of plant lectin research. Glycoconj J 37:533–551. https://doi.org/10.1007/s10719-020-09942-y10.1007/s10719-020-09942-y ↗
2. Gupta A, Sandhu RS (1997) A new high molecular weight agglutinin from garlic (Allium sativum). Mol Cell Biochem 166:1–9. https://doi.org/10.1023/a:100682792115110.1023/a:1006827921151 ↗
3. Gupta GS (2012) Animal lectins: form, function and clinical applications. Springer-Wien10.1007/978-3-7091-1065-2 ↗
4. Nizet V, Varki A, Aebi M (2017) Microbial lectins: hemagglutinins, adhesins, and toxins. In: A Varki, RD Cummings, JD Esko, (Eds) Essentials of glycobiology. 3rd ed. Cold Spring Harbor (NY), Ch 37.
5. Peumans WJ, Damme V (1995) EJM. Lectins as plant defence proteins. Plant Physiol 109:347–352. https://doi.org/10.1104/pp.109.2.34710.1104/pp.109.2.347 ↗
6. Gupta A (2020) Emerging applications of lectins in cancer detection and biomedicine. Mater Today: Proc 31:651–661. https://doi.org/10.1016/j.matpr.2020.05.81010.1016/j.matpr.2020.05.810 ↗
7. Muramoto K (2017) Lectins as bioactive proteins in foods and feeds. Food Sci Technol Res 23:487–494. https://doi.org/10.3136/fstr.23.48710.3136/fstr.23.487 ↗
8. Gupta A, Sandhu RS (1998) Effect of garlic agglutinin and garlic extracts on the rat jejunum. Nutr Res 18:841–850. https://doi.org/10.1016/s0271-5317(98)00069-410.1016/s0271-5317(98)00069-4 ↗
9. Gupta A, Sandhu RS (1997) In vivo binding of mannose specific lectin from garlic to intestinal epithelium. Nutr Res 17:703–711. https://doi.org/10.1016/S0271-5317(97)00040-710.1016/S0271-5317(97)00040-7 ↗
10. von Itzstein M (2008) Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design. Curr Opin Struct Biol 18:558–566. https://doi.org/10.1016/j.sbi.2008.07.00610.1016/j.sbi.2008.07.006 ↗
11. Lagarda-Diaz I, Guzman-Partida AM, Vazquez-Moreno L (2017) Legume lectins: proteins with diverse applications. Int J Mol Sci 18:1242–1260. https://doi.org/10.3390/ijms1806124210.3390/ijms18061242 ↗
12. Katoch R, Tripathi A (2021) Research advances and prospects of legume lectins. J Biosci 46(4):104. https://doi.org/10.1007/s12038-021-00225-810.1007/s12038-021-00225-8 ↗
13. Dias Rde O, Machado Ldos S et al (2015) Insights into animal and plant lectins with antimicrobial activities. Molecules 20:519–541. https://doi.org/10.3390/molecules2001051910.3390/molecules20010519 ↗
14. Cedzyński M, Świerzko AS (2020) Components of the lectin pathway of complement in haematologic malignancies. Cancers 12:1792–1810. https://doi.org/10.3390/cancers1207179210.3390/cancers12071792 ↗
15. Sampaolesi S, Nicotra F, Russo L (2019) Glycans in nanomedicine, impact and perspectives. Future Med Chem 11:43–60. https://doi.org/10.4155/fmc-2018-036810.4155/fmc-2018-0368 ↗
16. Hatton NE, Baumann CG, Fascione MA (2021) Developments in mannose-based treatments for uropathogenic Escherichia coli-induced urinary tract infections. ChemBioChem 22:613–629. https://doi.org/10.1002/cbic.20200040610.1002/cbic.202000406 ↗
17. Ofek I, Beachey EH (1978) Mannose binding and epithelial cell adherence of Escherichia coli. Infect Immun 22:247–254. https://doi.org/10.1128/iai.22.1.247-254.197810.1128/iai.22.1.247-254.1978 ↗
18. Ohlsen K, Oelschlaeger TA, Hacker J et al (2009) Carbohydrate receptors of bacterial adhesion: implications and reflections. Top Curr Chem 288:109–120. https://doi.org/10.1007/128_2008_1010.1007/128_2008_10 ↗
19. Hynes SO, Hirmo S, Wadstrom T et al (1999) Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. J Clin Microbiol 37:1994–1998. https://doi.org/10.1128/JCM.37.6.1994-1998.199910.1128/JCM.37.6.1994-1998.1999 ↗
20. Botos I, Wlodawer A (2005) Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 88:233–282. https://doi.org/10.1016/j.pbiomolbio.2004.05.00110.1016/j.pbiomolbio.2004.05.001 ↗
21. Tchesnokova V, Aprikian P, Kisiela D et al (2011) Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli. Infect Immun 79:3895–3904. https://doi.org/10.1128/IAI.05169-1110.1128/IAI.05169-11 ↗
22. Cuenot S, Bouvrée A, Bouchara JP (2017) Nanoscale mapping of multiple lectins on cell surfaces by single-molecule force spectroscopy. Adv Biosys 1:1700050. https://doi.org/10.1002/adbi.20170005010.1002/adbi.201700050 ↗
23. Gupta A, Gupta RK, Gupta GS (2009) Targeting cells for drug and gene delivery: emerging applications of mannans and mannan binding lectins. J Sci Indus Res 68:465–483
24. Barre A, Bourne Y, Van Damme EJM et al (2001) Mannose-binding plant lectins: different structural scaffolds for a common sugar-recognition process. Biochimie 83:645–651. https://doi.org/10.1016/s0300-9084(01)01315-310.1016/s0300-9084(01)01315-3 ↗
25. Barre A, Simplicien M, Benoist H et al (2019) Mannose-specific lectins from marine algae: diverse structural scaffolds associated to common virucidal and anti-cancer properties. Mar Drugs 17:440. https://doi.org/10.3390/md1708044010.3390/md17080440 ↗
26. Hwang HJ, Han JW, Jeon H et al (2020) Characterization of a novel mannose-lectin with antiviral activities from red alga Grateloupia chiangii. Biomolecules 10:333. https://doi.org/10.3390/biom1002033310.3390/biom10020333 ↗
27. Nabi-Afjadi M, Heydari M, Zalpoor H et al (2022) Lectins and lectibodies: potential promising antiviral agents. Cell Mol Biol Lett 27:37. https://doi.org/10.1186/s11658-022-00338-410.1186/s11658-022-00338-4 ↗
28. Martinez D, Amaral D, Markovitz D et al (2021) The use of lectins as tools to combat SARS-CoV-2. Curr Pharm Des 27(41):4212–4222. https://doi.org/10.2174/138161282766621083009474310.2174/1381612827666210830094743 ↗
29. Gupta A (2012) Collectins: mannan-binding protein as a model lectin. In: Gupta GS (ed) Animal lectins: form, function and clinical applications. Springer-Wien, pp 483–49910.1007/978-3-7091-1065-2_23 ↗
30. Stravalaci M, De Blasio D, Orsini V et al (2016) A new surface plasmon resonance assay for in vitro screening of mannose-binding lectin inhibitors. Biomol Screen 21:749–757. https://doi.org/10.1177/108705711663756310.1177/1087057116637563 ↗
31. Dørflinger GH, Holt CB, Thiel S et al (2017) Effect of optimization of glycaemic control on mannan-binding lectin in type 1 Diabetes. J Diabetes Res 2017:1249729. https://doi.org/10.1155/2017/124972910.1155/2017/1249729 ↗
32. De Blasio D, Fumagalli S, Longhi L et al (2017) Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury. J Cereb Blood Flow Metab 37:938–950. https://doi.org/10.1177/0271678X1664739710.1177/0271678X16647397 ↗
33. Meier M, Bider MD, Malashkevich VN et al (2000) Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol 300:857–865. https://doi.org/10.1006/jmbi.2000.385310.1006/jmbi.2000.3853 ↗
34. Wu J, Nantz MH, Zern MA (2002) Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 7:d717-725. https://doi.org/10.2741/A80610.2741/A806 ↗
35. Hu J, Wei P, Seeberger PH, Yin J (2018) Mannose-functionalized nanoscaffolds for targeted delivery in biomedical applications. Chem Asian J 13:3448–3459. https://doi.org/10.1002/asia.20180108810.1002/asia.201801088 ↗
36. Ip WK, Chan KH, Law HK et al (2005) Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191:1697–1704. https://doi.org/10.1086/42963110.1086/429631 ↗
37. Świerzko AS, Cedzyński M (2020) The influence of the lectin pathway of complement activation on infections of the respiratory system. Front Immunol 11:585243. https://doi.org/10.3389/fimmu.2020.58524310.3389/fimmu.2020.585243 ↗
38. Medetalibeyoglu A, Bahat G, Senkal N et al (2021) Mannose binding lectin gene 2 (rs1800450) missense variant may contribute to development and severity of COVID-19 infection. Infect Genet Evol 89:104717. https://doi.org/10.1016/j.meegid.2021.10471710.1016/j.meegid.2021.104717 ↗
39. Gupta A, Gupta GS (2021) Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Mol Cell Biochem 21:1–26. https://doi.org/10.1007/s11010-021-04107-310.1007/s11010-021-04107-3 ↗
40. Ambrosio AR, De Messias-Reason IJ (2005) Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation An antibody-independent defence mechanism. Parasite Immunol 27:333–340. https://doi.org/10.1111/j.1365-3024.2005.00782.x10.1111/j.1365-3024.2005.00782.x ↗
41. Zhang JX, Gong WP, Zhu DL et al (2020) Mannose-binding lectin 2 gene polymorphisms and their association with tuberculosis in a Chinese population. Infect Dis Poverty 9:46. https://doi.org/10.1186/s40249-020-00664-910.1186/s40249-020-00664-9 ↗
42. Ramos-Soriano J, Reina JJ, Illescas BM et al (2019) Synthesis of highly efficient multivalent disaccharide/[60] fullerene nanoballs for emergent viruses. J Am Chem Soc 141:15403–15412. https://doi.org/10.1021/jacs.9b0800310.1021/jacs.9b08003 ↗
43. Bhute VJ, Harte J, Houghton JW et al (2020) Mannose binding lectin is hydroxylated by collagen prolyl-4-hydroxylase and inhibited by some PHD inhibitors. KIDNEY360. 1:447–457. https://doi.org/10.34067/KID.000009202010.34067/KID.0000092020 ↗
44. Gupta RK, Gupta GS (2012) Mannose receptor family: R-type lectins. In: Gupta GS (ed) Animal lectins: form, function and clinical applications. Springer-Wien, pp 331–34710.1007/978-3-7091-1065-2_15 ↗
45. Boskovic J, Arnold JN, Stilion R et al (2006) Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor. J Biol Chem 28:8780–8787. https://doi.org/10.1074/jbc.M51327720010.1074/jbc.M513277200 ↗
46. Gupta RK, Gupta GS (2012) Dectin-1 receptor family. In: Gupta GS (ed) Animal lectins: form, function and clinical applications. Springer-Wien, pp 725–74710.1007/978-3-7091-1065-2_34 ↗
47. Gupta RK, Gupta GS (2012) Dendritic cell lectin receptors (dectin-2 receptors family). In: Gupta GS (ed) Animal lectins: form, function and clinical applications, Springer-Wien, pp 749–77110.1007/978-3-7091-1065-2_35 ↗
48. Huang X, Jain PK, El-Sayed IH et al (2007) Gold NPs: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine 2:681–693. https://doi.org/10.2217/17435889.2.5.68110.2217/17435889.2.5.681 ↗
49. Napper CE, Dyson MH, Taylor ME (2001) An extended conformation of the macrophage mannose receptor. J Biol Chem 276:14759–14766. https://doi.org/10.1074/jbc.M10042520010.1074/jbc.M100425200 ↗
50. Sedaghat B, Stephenson R, Toth I (2014) Targeting the mannose receptor with mannosylated subunit vaccines. Curr Med Chem 21:3405–3418. https://doi.org/10.2174/092986732166614082611555210.2174/0929867321666140826115552 ↗
51. Feinberg H, Mitchell DA, Drickamer K et al (2001) Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294:2163–2166. https://doi.org/10.1126/science.106637110.1126/science.1066371 ↗
52. Gupta RK, Gupta GS (2012) DC-SIGN family of receptors. In: Gupta GS (ed) Animal lectins: form, function and clinical applications. Springer-Wien, pp 773–79810.1007/978-3-7091-1065-2_36 ↗
53. Gupta RK, Gupta A (2012) Endogenous lectins as drug targets. In: Gupta GS (ed) Animal lectins: form, function and clinical applications. Springer-Wien, pp 1039–105710.1007/978-3-7091-1065-2_46 ↗
54. Dennehy KM, Brown GD (2007) The role of the β-glucan receptor dectin-1 in control of fungal infection. J Leuko Biol 82:253–258. https://doi.org/10.1189/jlb.120675310.1189/jlb.1206753 ↗
55. Blattes E, Vercellone A, Eutamène H et al (2013) Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment. Proc Natl Acad Sci USA 110:8795–8800. https://doi.org/10.1073/pnas.122170811010.1073/pnas.1221708110 ↗
56. Engleder E, Demmerer E, Wang X et al (2015) Determination of the glycosylation-pattern of the middle ear mucosa in guinea pigs. Int J Pharm 484:124–130. https://doi.org/10.1016/j.ijpharm.2015.02.05610.1016/j.ijpharm.2015.02.056 ↗
57. Gonzalez SF, Kornek VL, Kuligowski MP et al (2010) Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. Nat Immunol 11:427–434. https://doi.org/10.1038/ni.185610.1038/ni.1856 ↗
58. Tzeng CW, Tzeng WS, Lin LT et al (2016) Enhanced autophagic activity of artocarpin in human hepatocellular carcinoma cells through improving its solubility by a NP system. Phytomedicine 23:528–540. https://doi.org/10.1016/j.phymed.2016.02.01010.1016/j.phymed.2016.02.010 ↗
59. Kwankaew J, Phimnuan P, Wanauppathamkul S et al (2017) Formulation of chitosan patch incorporating Artocarpus altilis heartwood extract for improving hyperpigmentation. J Cosmet Sci 68:257–269
60. Omokawa Y, Miyazaki T, Walde P, Akiyama K, Sugahara T et al (2010) In vitro and in vivo anti-tumor effects of novel Span 80 vesicles containing immobilized Eucheuma serra agglutinin. Int J Pharm 389:157–167. https://doi.org/10.1016/j.ijpharm.2010.01.03310.1016/j.ijpharm.2010.01.033 ↗
61. Condori J, Acosta W, Ayala J et al (2016) Enzyme replacement for GM1-gangliosidosis: uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase: RTB lectin fusion. Mol Genet Metab 117:199–209. https://doi.org/10.1016/j.ymgme.2015.12.00210.1016/j.ymgme.2015.12.002 ↗
62. Acosta W, Ayala J, Dolan MC et al (2015) RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies. Sci Rep 5:14144. https://doi.org/10.1038/srep1414410.1038/srep14144 ↗
63. Bitsch M, Laursen I, Engel AM et al (2009) Epidemiology of chronic wound patients and relation to serum levels of mannan-binding lectin. Acta Derm Venereol 89:607–611. https://doi.org/10.2340/00015555-073010.2340/00015555-0730 ↗
64. Maaløe CB, Laursen I et al (2011) Mannan-binding lectin and healing of a radiation-induced chronic ulcer—a case report on mannan-binding lectin replacement therapy. Plast Reconstr Aesthet 64:e146–e148. https://doi.org/10.1016/j.bjps.2011.01.01310.1016/j.bjps.2011.01.013 ↗
65. Chahud F, Ramalho LNZ, Ramalho FS et al (2009) The lectin KM+ induces corneal epithelial wound healing in rabbits. Int J Exp Pathol 90:166–173. https://doi.org/10.1111/j.1365-2613.2008.00626.x10.1111/j.1365-2613.2008.00626.x ↗
66. Van EJ, Van Baardewijk LJ, Sier CF et al (2013) Bone healing and mannose-binding lectin. Int J Surg 11:296–300. https://doi.org/10.1016/j.ijsu.2013.02.02210.1016/j.ijsu.2013.02.022 ↗
67. Axelgaard E, Østergaard JA, Thiel S et al (2017) Diabetes is associated with increased autoreactivity of mannan-binding lectin. J Diabetes Res 2017:6368780. https://doi.org/10.1155/2017/636878010.1155/2017/6368780 ↗
68. Demir EF, Atay NO, Koruyucu M et al (2018) Mannose based polymeric nanoparticles for lectin separation. Sep Sci Technol 53:1–11. https://doi.org/10.1080/01496395.2018.145294310.1080/01496395.2018.1452943 ↗
69. Tetala KKR, Chen B, Visser GM et al (2007) Preparation of a monolithic capillary column with immobilized α-mannose for affinity chromatography of lectins. J Biochem Biophys Methods 70:63–69. https://doi.org/10.1016/j.jbbm.2006.09.00910.1016/j.jbbm.2006.09.009 ↗
70. Bamrungsap S, Zhao Z, Chen T et al (2012) A focus on NPs as a drug delivery system. Nanomedicine 7:1253–1271. https://doi.org/10.2217/nnm.12.8710.2217/nnm.12.87 ↗
71. Sinha R, Kim GJ, Nie S et al (2006) Nanotechnology in cancer therapeutics: bioconjugated NPs for drug delivery. Mol Cancer Ther 5:1909–1917. https://doi.org/10.1158/1535-7163.MCT-06-014110.1158/1535-7163.MCT-06-0141 ↗
72. Yilmaz G, Becer CR (2015) Glyconanoparticles and their interactions with lectins. Polym Chem 6:5503–5514. https://doi.org/10.1039/c5py00089k10.1039/c5py00089k ↗
73. Cho K, Wang X, Nie S et al (2008) Therapeutic NPs for drug delivery in cancer. Clin Cancer Res 14:1310–1316. https://doi.org/10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
74. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded NPs is mediated via sustained intracellular drug retention. Mol Pharm 2:373–383. https://doi.org/10.1021/mp050032z10.1021/mp050032z ↗
75. Smith AM, Duan H, Mohs AM et al (2008) Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev 60:1226–1240. https://doi.org/10.1016/j.addr.2008.03.01510.1016/j.addr.2008.03.015 ↗
76. Kubik T, Bogunia K, Sugisaka M (2005) Nanotechnology on duty in medical applications. Curr Pharm Biotechnol 6:17–33. https://doi.org/10.2174/138920105316724810.2174/1389201053167248 ↗
77. Yatvin MB, Kreut W, Horwitz BA et al (1980) pH-sensitive liposomes: possible clinical implications. Science 10:1253–1255. https://doi.org/10.1126/science.743402510.1126/science.7434025 ↗
78. Salata O (2004) Applications of nanoparticles in biology and medicine. J Nanobiotechnol 2:3. https://doi.org/10.1186/1477-3155-2-310.1186/1477-3155-2-3 ↗
79. Khan I, Khalid S, Idrees K (2019) Nanoparticles: properties, applications and toxicities. Arab J Chem 12:908–931. https://doi.org/10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
80. Cha C, Shin SR, Annabi N et al (2013) Carbon-based nanomaterials: multi-functional materials for biomedical engineering. ACS Nano 7:2891–2897. https://doi.org/10.1021/nn401196a10.1021/nn401196a ↗
81. Andersen AJ, Robinson JT, Dai H et al (2013) Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7:1108–1119. https://doi.org/10.1021/nn305517510.1021/nn3055175 ↗
82. Fard MG, Khabir Z, Reineck P et al (2022) Targeting cell surface glycans with lectin-coated fluorescent nanodiamonds. Nanoscale Adv 4:1551–1564. https://doi.org/10.1039/d2na00036a10.1039/d2na00036a ↗
83. Tripathi SK, Kaur G, Khurana RK, Kapoor S, Singh B (2015) Quantum dots and their potential role in cancer theranostics. Crit Rev Ther Drug Carr Sys 32:461–502. https://doi.org/10.1615/critrevtherdrugcarriersyst.201501236010.1615/critrevtherdrugcarriersyst.2015012360 ↗
84. Toraskar S, Gade M, Sangabathuni S, Thulasiram HV, Kikkeri R (2017) Exploring the influence of shapes and heterogeneity of glyco-gold nanoparticles on bacterial binding for preventing infections. Chem Med Chem 12(14):1116–1124. https://doi.org/10.1002/cmdc.20170021810.1002/cmdc.201700218 ↗
85. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633–4646. https://doi.org/10.1038/sj.onc.120959710.1038/sj.onc.1209597 ↗
86. Alnashiri HM, Aldakheel FM, Binshaya AS, Alharthi NS, Ahmed M (2022) Antimicrobial analysis of biosynthesized lectin-conjugated gold nanoparticles. Adsorp Sci Technol 8187260. https://doi.org/10.1155/2022/818726010.1155/2022/8187260 ↗
87. Barboiu M, Mouline Z, Silion M et al (2014) Multivalent recognition of concanavalin A by Mo132 glyconanocapsules—toward biomimetic hybrid multilayers. Chemistry 20:6678–6683. https://doi.org/10.1002/chem.20140218710.1002/chem.201402187 ↗
88. Chao Y, Karmali PP, Simberg D (2012) Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles. Adv Exp Med Biol 733:115–123. https://doi.org/10.1007/978-94-007-2555-3_1110.1007/978-94-007-2555-3_11 ↗
89. Thomas SC, Harshita MPK et al (2015) Ceramic nanoparticles: fabrication methods and applications in drug delivery. Curr Pharm Des 21:6165–618810.2174/1381612821666151027153246 ↗
90. Rawat M, Singh D, Saraf S et al (2006) Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 29:1790–1798. https://doi.org/10.1248/bpb.29.179010.1248/bpb.29.1790 ↗
91. Jores K, Mehnert W, Drechsler M et al (2004) Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 95:217–227. https://doi.org/10.1016/j.jconrel.2003.11.01210.1016/j.jconrel.2003.11.012 ↗
92. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803. https://doi.org/10.1200/JCO.2005.04.93710.1200/JCO.2005.04.937 ↗
93. Sabbatini P, Aghajanian C, Dizon D et al (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22:4523–4531. https://doi.org/10.1200/JCO.2004.12.04310.1200/JCO.2004.12.043 ↗
94. Bhatt R, de Vries P, Tulinsky J et al (2003) Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J Med Chem 46:190–193. https://doi.org/10.1021/jm020022r10.1021/jm020022r ↗
95. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–360. https://doi.org/10.1038/nrd108810.1038/nrd1088 ↗
96. Chen Y, Liu L (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64:640–665. https://doi.org/10.1016/j.addr.2011.11.01010.1016/j.addr.2011.11.010 ↗
97. Mohamed F, van der Walle CF (2008) Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 97:71–87. https://doi.org/10.1002/jps.2108210.1002/jps.21082 ↗
98. Pillay S, Pillay V, Choonara YE et al (2009) Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm 382:277–290. https://doi.org/10.1016/j.ijpharm.2009.08.02110.1016/j.ijpharm.2009.08.021 ↗
99. Chen J, Zhang C, Liu Q et al (2012) Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. J Drug Target 20:174–184. https://doi.org/10.3109/1061186X.2011.62239610.3109/1061186X.2011.622396 ↗
100. Yang R, Xu J, Xu L et al (2018) Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano 26:5121–5129. https://doi.org/10.1021/acsnano.7b0904110.1021/acsnano.7b09041 ↗